RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

As bad as things have seemed at times, 2007 has the potential to be a watershed year for Cortex. First though, we need to get through a difficult period - probably a PIPE sometime in the next 3 months, and getting the primate studies done and dosing restrictions lifted. Once past those obstacles, the path is then wide open for a good BP deal and a nice move up in the shareprice.

Of course complicating the picture in 2007 to some extent will be the non-Ampakine in-license activity. Other factors are the Org-24448 Schizo results, which one would expect to be published before too long.

One thing I've learned in bio investing is patience, and patience is a lot easier with a diversified portfolio.